The Lancet in conversation with
Jessamy Bagenal, Chloe Wilson, and Callum Davidson—editors at The Lancet—and Gavin Cleaver, The Lancet Group’s Audio Producer, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.
A monthly audio companion to the journal, this podcast covers topics that advance the field of medical research, from exploring treatments to examining drug trials, public health outbreaks to surgical techniques, and more.
Podcasting since 2006 • 661 episodes
The Lancet in conversation with
Latest Episodes
Presented at ASCO: the first RCT of CAR T-cell therapy in solid tumours
Changsong Qi joins Chloe Wilson and Ben Abbott of The Lancet to discuss their recently published phase 2 randomised controlled trial investigating Claudin-18 isoform 2-specific CAR T-cell therapy for previously treated advanced gastric...
•
14:45
Previewing ASCO 2025
Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, joins Gavin Cleaver to discuss what's being published at this year's American Society of Clinical Oncology (ASCO) meeting, what she's excited to...
•
4:54
Francis Couturaud on treatment of venous thromboembolism
Francis Couturaud joins Chloe Wilson of The Lancet to discuss the RENOVE trial, which looks at assessing the efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended anticoagulation h...
•
28:30
Shawn St Peter on appendicectomy versus antibiotics for acute uncomplicated appendicitis in children
This week, we discuss treatment approaches for uncomplicated appendicitis in children following the publication of a trial in our January 18th issue. Lead author Shawn St Peter, general paediatric surgeon and surgeon-in-chief at Children’s Merc...
•
16:01
Michael Heneka on passive anti-amyloid β immunotherapy in Alzheimer’s disease
Michael Heneka joins Chloe Wilson and Bea Gomez Perez-Nievas of The Lancet to discuss a therapeutics paper discussing the opportunities and challenges of passive anti-amyloid β immunotherapy in Alzheimer's disease.Read the full...
•
21:35